Medpace Holdings, Inc. $MEDP Holdings Lifted by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 14.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,861 shares of the company’s stock after buying an additional 7,194 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.20% of Medpace worth $28,721,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Norges Bank purchased a new position in Medpace during the 2nd quarter valued at about $66,597,000. Clarkston Capital Partners LLC purchased a new position in Medpace during the second quarter valued at approximately $40,569,000. Mawer Investment Management Ltd. grew its position in Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares in the last quarter. Bares Capital Management Inc. increased its stake in Medpace by 319.2% in the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after buying an additional 119,608 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Medpace by 79.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock worth $83,258,000 after buying an additional 117,301 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Mizuho set a $660.00 price target on Medpace in a research note on Friday, January 9th. Finally, TD Cowen reiterated a “sell” rating on shares of Medpace in a report on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $491.27.

Insider Activity at Medpace

In related news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the transaction, the president owned 15,000 shares in the company, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 351,235 shares of company stock valued at $211,280,506. Corporate insiders own 20.30% of the company’s stock.

Medpace Price Performance

Medpace stock opened at $588.05 on Monday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The company’s fifty day moving average price is $583.65 and its two-hundred day moving average price is $522.67. The company has a market capitalization of $16.57 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 1.97 and a beta of 1.43.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.